Literature DB >> 32547653

Importance of pleural findings in patients with amyloid cardiomyopathy complicated with refractory pleural effusion.

Hikari Noda1, Manabu Nitta1, Yuka Taguchi1, Katsumi Matsumoto1, Teruyasu Sugano1, Tomoaki Ishigami1, Toshiyuki Ishikawa1, Koichi Tamura1, Kazuo Kimura1.   

Abstract

A 76-year-old male was admitted to our hospital for progressive bilateral pleural effusion. Because of typical echocardiographic findings such as left ventricular (LV) hypertrophy, thickness of the mitral valve, and a granular sparkling appearance of the LV wall, amyloid cardiomyopathy was suspected. Regardless of up-titration of several diuretic agents, the bilateral pleural effusion did not improve. Because the histological findings of the right ventricular septum (direct-fast-scarlet staining) obtained by biopsy that demonstrated amyloid deposits in perivascular and pericellular lesions, amyloid cardiomyopathy was diagnosed. However, cardiac catheterization revealed normal right and left atrial pressure and normal right and left ventricular end-diastolic pressure. Therefore, hemodynamic deterioration was less likely to be the cause of persistent pleural effusion. Amyloid deposits were also detected in the pleural biopsy specimen, so pleural amyloidosis was diagnosed and may have played an important role in the refractoriness of the pleural effusion. <Learning objective: Systolic and diastolic dysfunction of various degrees can occur in patients with amyloid cardiomyopathy, which is usually progressive and induces heart failure. In these patients, diuretics are key drugs for resolving fluid retention issues such as pleural effusion. In cases of refractory pleural effusion associated with amyloid cardiomyopathy despite aggressive diuretic therapy, these may be induced by pleural amyloidosis.>.
© 2020 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Pleural amyloidosis; Refractory pleural effusion; Systemic amyloidosis

Year:  2020        PMID: 32547653      PMCID: PMC7283287          DOI: 10.1016/j.jccase.2020.01.003

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  9 in total

Review 1.  Amyloid diseases of the heart: assessment, diagnosis, and referral.

Authors:  S W Dubrey; P N Hawkins; R H Falk
Journal:  Heart       Date:  2011-01       Impact factor: 5.994

2.  The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement.

Authors:  S W Dubrey; K Cha; J Anderson; B Chamarthi; J Reisinger; M Skinner; R H Falk
Journal:  QJM       Date:  1998-02

Review 3.  Pleural effusions in systemic amyloidosis.

Authors:  John L Berk
Journal:  Curr Opin Pulm Med       Date:  2005-07       Impact factor: 3.155

4.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

5.  Type and distribution of pulmonary parenchymal and vascular amyloid. Correlation with cardiac amyloid.

Authors:  R R Smith; G M Hutchins; G W Moore; R L Humphrey
Journal:  Am J Med       Date:  1979-01       Impact factor: 4.965

Review 6.  Amyloid, amyloidosis, and amyloidogenesis.

Authors:  G G Glenner; D L Page
Journal:  Int Rev Exp Pathol       Date:  1976

7.  [Successful treatment of pleurodesis for seemingly intractable pleural effusion in pleural amyloidosis with rheumatoid arthritis].

Authors:  Aiko Masunaga; Nahoko Takeda; Kimitaka Akaike; Kaori Tsumori; Eisuke Goto; Hidenori Ichiyasu; Hirotsugu Kohrogi
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2011-12

8.  Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis.

Authors:  John L Berk; Joseph Keane; David C Seldin; Vaishali Sanchorawala; Jun Koyama; Laura M Dember; Rodney H Falk
Journal:  Chest       Date:  2003-09       Impact factor: 9.410

Review 9.  The role of pleurodesis in respiratory diseases.

Authors:  Rachel M Mercer; Maged Hassan; Najib M Rahman
Journal:  Expert Rev Respir Med       Date:  2018-02-28       Impact factor: 3.772

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.